Sumit Sheoran | Cancer Biomarkers | Innovative Research Award

Published on by Oncology

Innovative Research Award

Sumit Sheoran
Babasaheb Bhimrao Ambedkar University

                          Sumit Sheoran
Affiliation Babasaheb Bhimrao Ambedkar University
Country India
Scopus ID 57755350400
Documents 10
Citations 188
h-index 5
Subject Area Cancer Biomarkers
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0002-2519-8506

The Innovative Research Award recognizes emerging and impactful scientific contributions in oncology-related research. Sumit Sheoran has established a scholarly profile in cancer biomarker investigations, with publications indexed in major academic databases and measurable citation impact. His research activities demonstrate engagement with molecular oncology, biomarker discovery, and translational biomedical science, contributing to the broader understanding of cancer diagnosis and therapeutic development.[1][2]

Abstract

Sumit Sheoran is a researcher associated with Babasaheb Bhimrao Ambedkar University whose academic activities focus on cancer biomarkers and related biomedical investigations. His scholarly record includes peer-reviewed publications indexed in Scopus, demonstrating contributions to oncology-oriented research and translational scientific studies. With documented citation performance and a growing research profile, his work supports ongoing efforts to improve understanding of disease mechanisms, biomarker identification, and evidence-based clinical applications. The combination of publication output, citation recognition, and engagement in cancer research highlights a profile aligned with contemporary priorities in oncology and biomedical innovation.[1][2]

Keywords

  • Cancer Biomarkers
  • Oncology Research
  • Translational Medicine
  • Molecular Diagnostics
  • Biomedical Research
  • Cancer Biology

Introduction

Cancer biomarker research plays a central role in advancing precision medicine, early diagnosis, prognostic assessment, and therapeutic monitoring. Sumit Sheoran’s academic work is positioned within this evolving field, emphasizing scientific inquiry that contributes to the understanding of cancer-related biological processes. Through peer-reviewed publications and scholarly engagement, his research supports evidence generation relevant to contemporary oncology challenges and emerging diagnostic strategies.[1]

Research Profile

Affiliated with Babasaheb Bhimrao Ambedkar University, Sumit Sheoran maintains a documented scholarly presence through Scopus, ORCID, Google Scholar, and ResearchGate profiles. His publication record includes ten indexed documents with citation activity reflecting academic visibility. The research profile demonstrates continued participation in oncology-related investigations and interdisciplinary biomedical research initiatives.[1][2]

Research Contributions

The research contributions of Sumit Sheoran are associated with cancer biomarker discovery, molecular characterization, and biomedical investigations relevant to oncology. His scholarly outputs contribute to scientific discussions concerning disease detection, biomarker validation, and translational research applications. These efforts support broader objectives aimed at improving diagnostic accuracy and strengthening evidence-based cancer research frameworks.[1]

Publications

The researcher has produced ten Scopus-indexed publications addressing themes related to cancer biomarkers and biomedical sciences. These publications have accumulated citation recognition within the scholarly community and contribute to the dissemination of scientific knowledge. Publication activity demonstrates sustained participation in peer-reviewed research and academic communication within relevant scientific disciplines.[1]

Research Impact

Research impact is reflected through documented citation metrics, publication visibility, and engagement within oncology research networks. With 188 citations and an h-index of 5, the available bibliometric indicators suggest that the research outputs have contributed to ongoing scientific discourse. Such indicators provide evidence of academic relevance and scholarly recognition.[3]

Award Suitability

The Innovative Research Award emphasizes scientific originality, measurable research outcomes, and disciplinary relevance. Sumit Sheoran’s documented publication record, citation performance, and specialization in cancer biomarkers align with these evaluation dimensions. His contributions to oncology-focused research provide a reasonable basis for consideration within an international research recognition framework.[1][4]

Conclusion

Sumit Sheoran has developed an emerging research profile characterized by contributions to cancer biomarker studies, peer-reviewed publications, and measurable citation impact. His scholarly activities support the advancement of oncology research and demonstrate alignment with the objectives of international scientific recognition programs that value innovation, research quality, and academic engagement.[1][2]

References

  1. Elsevier. (n.d.). Scopus author details: Sumit Sheoran, Author ID 57755350400. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57755350400
  2. ORCID. (n.d.). Sumit Sheoran: ORCID record 0000-0002-2519-8506.
    https://orcid.org/0000-0002-2519-8506
  3. Google Scholar. (n.d.). Scholar profile of Sumit Sheoran.
    https://scholar.google.com/citations?hl=en&user=sz3r5rQAAAAJ
  4. ResearchGate. (n.d.). Sumit Sheoran research profile and scholarly outputs.
    https://www.researchgate.net/profile/Sumit-Sheoran-8

Biomedical Advancements in Cancer

Published on by Oncology

Biomedical Advancements in Cancer

 

Introduction: In recent years, the field of biomedical advancements in cancer research has witnessed remarkable breakthroughs that have transformed our understanding of the disease and revolutionized treatment options. These advancements offer new hope to patients and hold the promise of improved outcomes in the fight against cancer.

Subtopics in Biomedical Advancements in Cancer:

Immunotherapy and Immune Checkpoint Inhibitors: Immune checkpoint inhibitors have emerged as a game-changer in cancer treatment, leveraging the body’s immune system to target and eliminate cancer cells. CAR-T cell therapy, PD-1 inhibitors, and CTLA-4 inhibitors are some of the key developments in this area.

Precision Medicine and Genomic Profiling: Advancements in genomic sequencing technologies have paved the way for precision medicine in cancer treatment. Tailoring therapies based on the genetic makeup of a patient’s tumor has improved treatment efficacy and reduced side effects.

Liquid Biopsies for Early Detection: Liquid biopsies involve the non-invasive analysis of blood or other bodily fluids to detect cancer-related genetic mutations and biomarkers. These tests offer early detection capabilities and real-time monitoring of cancer progression.

Targeted Therapies and Personalized Cancer Drugs: Targeted therapies are designed to specifically inhibit the molecular pathways driving cancer growth. Advances in drug development have led to a wide range of targeted treatments, enhancing the effectiveness of cancer therapy while minimizing collateral damage to healthy cells.

AI and Machine Learning in Cancer Diagnosis and Treatment: Artificial intelligence and machine learning algorithms are being employed to analyze vast datasets of medical information, aiding in early cancer diagnosis, treatment planning, and predicting patient outcomes. These technologies have the potential to optimize cancer care and streamline research efforts.

These subtopics represent just a fraction of the exciting developments in the biomedical field related to cancer research. Continued research and innovation in these areas are bringing us closer to more effective treatments, early detection methods, and improved patient outcomes in the battle against cancer.

Drug Design and Clinical Trials

Published on by Oncology

Drug Design and Clinical Trials

 

Introduction: Drug Design and Clinical Trials

The field of drug design and clinical trials represents a crucial bridge between scientific innovation and the improvement of human health. It encompasses the intricate processes involved in developing new pharmaceutical agents, assessing their safety and efficacy, and ultimately bringing them to the patients who need them. This dynamic and collaborative field plays a pivotal role in advancing medical treatments and therapeutics for a wide range of diseases and conditions.

Subtopics:

Rational Drug Design: Rational drug design involves the targeted creation of new drugs based on a deep understanding of the biological mechanisms underlying diseases. This subtopic explores the principles and techniques used in designing drugs with enhanced specificity and effectiveness.

Preclinical Testing: Before advancing to human trials, potential drug candidates undergo rigorous preclinical testing. This subtopic discusses the various stages of preclinical testing, including in vitro and animal studies, to evaluate safety and efficacy.

Clinical Trial Phases: Clinical trials are divided into phases, each serving a distinct purpose. This subtopic outlines the different phases (Phase I, II, III, and IV) of clinical trials, highlighting their objectives and the types of participants involved.

Patient Recruitment and Informed Consent: The recruitment of participants and obtaining informed consent are critical ethical aspects of clinical trials. This subtopic explores the importance of ethical considerations, participant rights, and the informed consent process in clinical research.

Data Analysis and Regulatory Approval: After the completion of clinical trials, data analysis and regulatory approval processes determine the fate of a drug candidate. This subtopic delves into the statistical methodologies used to analyze trial data and the regulatory agencies responsible for approving new drugs for market release.